Tags

Type your tag names separated by a space and hit enter

Tonabersat, a novel gap-junction modulator for the prevention of migraine.
Cephalalgia 2009; 29 Suppl 2:28-35C

Abstract

Migraine is a common, recurrent, primary headache disorder associated with significant morbidity as well as high direct and indirect costs. Despite its impact, only a proportion of migraineurs who meet criteria for prophylactic treatment take preventive medication. Antiepileptic drugs and beta-blockers are among the most used preventive therapies, but their exact mechanisms of action in migraine prophylaxis are unknown. Recent research has pointed to the role of cortical spreading depression in the genesis of migraine aura and pain, with neuronal-glial gap junctions playing a prominent part in cortical spreading depression. Tonabersat is a unique compound with demonstrated activity as a gap-junction inhibitor in animal studies. In preclinical and clinical trials, tonabersat was well tolerated, with no cardiovascular effects; the pharmacokinetic profile suggested its usefulness in the prophylaxis of migraine.

Links

  • Publisher Full Text
    • Aggregator Full Text

    Authors+Show Affiliations

    Silberstein SD
    Jefferson Headache Center, Philadelphia, PA 19107, USA. stephen.silberstein@jefferson.edu

    MeSH

    AnalgesicsAnimalsBenzamidesBenzopyransBrainClinical Trials as TopicCortical Spreading DepressionGap JunctionsGuidelines as TopicHumansMigraine Disorders

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    19723123

    Citation

    Silberstein, S D.. "Tonabersat, a Novel Gap-junction Modulator for the Prevention of Migraine." Cephalalgia : an International Journal of Headache, vol. 29 Suppl 2, 2009, pp. 28-35.
    Silberstein SD. Tonabersat, a novel gap-junction modulator for the prevention of migraine. Cephalalgia. 2009;29 Suppl 2:28-35.
    Silberstein, S. D. (2009). Tonabersat, a novel gap-junction modulator for the prevention of migraine. Cephalalgia : an International Journal of Headache, 29 Suppl 2, pp. 28-35. doi:10.1111/j.1468-2982.2009.01973.x.
    Silberstein SD. Tonabersat, a Novel Gap-junction Modulator for the Prevention of Migraine. Cephalalgia. 2009;29 Suppl 2:28-35. PubMed PMID: 19723123.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Tonabersat, a novel gap-junction modulator for the prevention of migraine. A1 - Silberstein,S D, PY - 2009/9/3/entrez PY - 2009/9/3/pubmed PY - 2009/11/18/medline SP - 28 EP - 35 JF - Cephalalgia : an international journal of headache JO - Cephalalgia VL - 29 Suppl 2 N2 - Migraine is a common, recurrent, primary headache disorder associated with significant morbidity as well as high direct and indirect costs. Despite its impact, only a proportion of migraineurs who meet criteria for prophylactic treatment take preventive medication. Antiepileptic drugs and beta-blockers are among the most used preventive therapies, but their exact mechanisms of action in migraine prophylaxis are unknown. Recent research has pointed to the role of cortical spreading depression in the genesis of migraine aura and pain, with neuronal-glial gap junctions playing a prominent part in cortical spreading depression. Tonabersat is a unique compound with demonstrated activity as a gap-junction inhibitor in animal studies. In preclinical and clinical trials, tonabersat was well tolerated, with no cardiovascular effects; the pharmacokinetic profile suggested its usefulness in the prophylaxis of migraine. SN - 1468-2982 UR - https://www.unboundmedicine.com/medline/citation/19723123/Tonabersat_a_novel_gap_junction_modulator_for_the_prevention_of_migraine_ L2 - http://journals.sagepub.com/doi/full/10.1111/j.1468-2982.2009.01973.x?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -